Ohio Medicaid does not cover Wegovy or Zepbound for weight loss

Ohio's Medicaid pharmacy rule lists drugs for the treatment of obesity as non-covered, and the Unified Preferred Drug List effective Oct. 1, 2026 lists Wegovy only in a class for non-obesity uses (cardiovascular risk reduction and MASH), with prior authorization. Zepbound, Saxenda and Foundayo do not appear on the list.123

Wegovy is covered only through the Metabolic Modifier Agents class for non-obesity uses, with clinical prior authorization approved for 180 days; the same criteria apply in fee-for-service and every Medicaid managed care plan.2345

• Wegovy, cardiovascular path: age 18 or older, BMI of 27 or more, a documented history of heart attack, stroke or symptomatic peripheral artery disease, current standard cardiovascular care, and no other GLP-1 at the same time.
• Wegovy, MASH path: age 18 or older, noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) confirmed by a liver biopsy in the last 24 months or by two listed non-invasive tests, diet and activity counseling, and no other MASH drug or GLP-1 at the same time.
• Wegovy is not authorized for patients with type 1 or type 2 diabetes, who are sent to the diabetes drug class instead; the 7.2 mg Wegovy dose is excluded.
• Renewal (both paths): at least 5% weight loss from baseline and claims showing at least 80% of days covered; MASH renewals also need a documented improvement in the liver disease.
• Non-preferred diabetes GLP-1s (Ozempic, Mounjaro, Rybelsus): at least 120 days without reaching the A1C goal on at least three preferred diabetes drugs, with a current A1C from the last 6 months; approved for 365 days.

Coverage for other uses the FDA has approved:

• Wegovy (injection), cardiovascular risk reduction in adults with established cardiovascular disease and a BMI of 27 or more, without diabetes: Covered with prior authorization23
• Wegovy (injection), noncirrhotic MASH with moderate to advanced liver fibrosis: Covered with prior authorization24
• Wegovy tablets, cardiovascular risk reduction in adults with established cardiovascular disease and a BMI of 27 or more, without diabetes: Covered with prior authorization23

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page lists no participating states, and we found no Ohio Department of Medicaid announcement that Ohio has joined.8

Since July 1, 2025, the state employee plan has not covered GLP-1 medications for weight loss, such as Wegovy, Zepbound and Saxenda. Members can join a Virta weight loss program at no cost, and employees prescribed a GLP-1 through Virta buy it from the manufacturer outside the plan and may apply for a partial, taxable reimbursement of up to $200, open to 2,500 employees at a time. From July 1, 2026, members must be enrolled in Virta's type 2 diabetes program to get diabetes GLP-1s such as Mounjaro and Ozempic at a $0 copay.91011121314

Pharmacy benefit: OptumRx (prescription drug); Anthem and Medical Mutual of Ohio (medical third-party administrators).

Marketplace (ACA) plans: Ohio's essential health benefits benchmark plan, an Anthem Blue Cross and Blue Shield small-group PPO used for plan years 2017 to 2026, excludes any drug that is primarily for weight loss.18

On the Unified Preferred Drug List effective Oct. 1, 2026, Trulicity, Victoza, generic liraglutide, Byetta and exenatide are preferred with no prior authorization; Ozempic, Mounjaro and Rybelsus are non-preferred and need prior authorization. Mounjaro also needs an A1C above 7% and at least 120 days on Ozempic, or a documented reason Ozempic can't be used.56

In 2025, Ohio Medicaid paid for 420,603 GLP-1 prescriptions, $404.6 million before rebates: 35 per 1,000 residents, against 32 across the states and DC, 17th of 51.66 It reimbursed 9 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 48 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4142323328362131

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2829302136373839403534
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.232521

In 2024, Medicare Part D drug plans paid for 851,928 GLP-1 claims from prescribers in Ohio, $1.06 billion in total drug cost.67

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.71 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Ohio on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7273 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 3 outsourcing facilities (503B) in Ohio, as of November 6, 2026; 1 show no inspection date and 2 were issued a Form 483.68

FDA warning letters naming a GLP-1, sent to a company in Ohio:69